A recent study proposed the combined use of two cell-cycle arrest biomarkers, insulin growth factor-binding protein 7 (IGFBP7), and tissue inhibitor of metalloproteinase 2 (TIMP-2) to predict the onset of severe AKI with significantly greater accuracy than other biomarkers [23]. This evidence concerns the gene TIMP2 and acute kidney injury.